These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20840868)

  • 21. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer.
    Bemelmans AP; Horellou P; Pradier L; Brunet I; Colin P; Mallet J
    Hum Gene Ther; 1999 Dec; 10(18):2987-97. PubMed ID: 10609659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model.
    Lee ST; Chu K; Park JE; Lee K; Kang L; Kim SU; Kim M
    Neurosci Res; 2005 Jul; 52(3):243-9. PubMed ID: 15896865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
    Ebert AD; Barber AE; Heins BM; Svendsen CN
    Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease Modification Through Trophic Factor Delivery.
    Savolainen M; Emerich D; Kordower JH
    Methods Mol Biol; 2018; 1780():525-547. PubMed ID: 29856034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.
    Emerich DF; Lindner MD; Winn SR; Chen EY; Frydel BR; Kordower JH
    J Neurosci; 1996 Aug; 16(16):5168-81. PubMed ID: 8756445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease.
    McBride JL; Behrstock SP; Chen EY; Jakel RJ; Siegel I; Svendsen CN; Kordower JH
    J Comp Neurol; 2004 Jul; 475(2):211-9. PubMed ID: 15211462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciliary neurotrophic factor protects striatal neurons against excitotoxicity by enhancing glial glutamate uptake.
    Beurrier C; Faideau M; Bennouar KE; Escartin C; Kerkerian-Le Goff L; Bonvento G; Gubellini P
    PLoS One; 2010 Jan; 5(1):e8550. PubMed ID: 20062544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.
    Alberch J; Pérez-Navarro E; Canals JM
    Brain Res Bull; 2002 Apr; 57(6):817-22. PubMed ID: 12031278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
    Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
    Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
    Pérez-Navarro E; Akerud P; Marco S; Canals JM; Tolosa E; Arenas E; Alberch J
    Neuroscience; 2000; 98(1):89-96. PubMed ID: 10858615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning.
    Kells AP; Connor B
    Neurosci Lett; 2008 May; 436(3):326-30. PubMed ID: 18406531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
    Anderson KD; Panayotatos N; Corcoran TL; Lindsay RM; Wiegand SJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7346-51. PubMed ID: 8692996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.
    McBride JL; During MJ; Wuu J; Chen EY; Leurgans SE; Kordower JH
    Exp Neurol; 2003 Jun; 181(2):213-23. PubMed ID: 12781994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
    Verma MK; Goel R; Nandakumar K; Nemmani KVS
    Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types.
    Figueredo-Cardenas G; Harris CL; Anderson KD; Reiner A
    Exp Neurol; 1998 Feb; 149(2):356-72. PubMed ID: 9500958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis.
    Schackel S; Pauly MC; Piroth T; Nikkhah G; Döbrössy MD
    Behav Brain Res; 2013 Nov; 256():56-63. PubMed ID: 23916743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
    Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
    Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.